ALS ONE will join the ALS Network to expand ALS research efforts, improve patient services, and strengthen nationwide ...

NEW YORK, May 6, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced its participation in ...

A study is exploring why athletes, first responders, and other high performers face an increased risk of developing ALS.

Virtual Webinar on Tuesday, Feb. 17 at 3 p.m. ET / 12 p.m. PT─ Will feature discussion and insights from Fred Grossman, D.O., FAPA; Stanley Appel, M.D.; and James Berry, M.D., MPH — accomplished ...

After Apellis Pharmaceuticals and partner Sobi ran into a clinical setback and ended the open-label extension arm of a study testing their amyotrophic lateral sclerosis (ALS) candidate, the companies ...

This groundbreaking discovery has revealed a systemic metabolic dysfunction that creates a toxic exosome cargo in ALS ...

Athira Pharma, Inc. has announced favorable results from a Phase 1 clinical trial of its drug candidate ATH-1105, which targets neurodegenerative diseases like amyotrophic lateral sclerosis (ALS). The ...

Cambridge, Mass., July 02, 2025 (GLOBE NEWSWIRE) -- A team of researchers from the MIT Sloan School of Management, the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital (MGH), ...

SALT LAKE CITY, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical ...

CINCINNATI--(BUSINESS WIRE)-- Asha Therapeutics (Asha), a life sciences company pioneering breakthrough therapeutics for neurological disease, announced today the company has been awarded a grant from ...

HERSHEY, Pa. — A toxic version of a certain protein may affect brain, spinal cord and skeletal muscle tissues differently, leading to the complex development and progression of amyotrophic lateral ...

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (“Coya”), a clinical-stage biotechnology company today announced successful meetings with the U.S. Food and Drug Administration (FDA) following a ...